Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SINTX TechnologiesSINT -8.50%27 3-Year EBITDA Growth Rate is 91.40% as of Mar. 2026, which is 3% above its 10-year median of 88.60. GuruFocus rates SINT with a GF Score™ of 27/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 692 Medical Devices & Instruments companies, SINTX Technologies ranks better than 97.98% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 91.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 82.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of SINTX Technologies was 91.40% per year. The lowest was 64.20% per year. And the median was 88.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
SINTX Technologies 3-Year EBITDA Growth Rate Related Terms
SINT vs ALRTF, CODX, PMI: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, SINTX Technologies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SINTX Technologies 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SINTX Technologies's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where SINTX Technologies's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 91.40% mean?
SINTX Technologies (SINT) has a 3-Year EBITDA Growth Rate of 91.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for SINTX Technologies and its competitors. This is near median its historical median of 88.60. Over the past decade, SINTX Technologies' 3-Year EBITDA Growth Rate has ranged from 64.20 to 91.40. According to the industry distribution chart, SINTX Technologies ranks #14 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 2%.
Is SINTX Technologies' 3-Year EBITDA Growth Rate too high?
SINTX Technologies' current 3-Year EBITDA Growth Rate of 91.40% is near median its 10-year median of 88.60. Over the past 10 years, this metric has ranged from a low of 64.20 to a high of 91.40. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.65. SINTX Technologies' value of 91.40% is 1094.8% above this industry median. Based on the distribution chart, SINTX Technologies ranks #14 out of 692 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, SINTX Technologies has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SINTX Technologies' 3-Year EBITDA Growth Rate compare to ALRTF and CODX?
According to the Medical Devices & Instruments industry distribution chart, SINTX Technologies ranks #14 out of 692 companies for 3-Year EBITDA Growth Rate. This places SINTX Technologies in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 7.65. SINTX Technologies' value of 91.40% is 1094.8% above this benchmark. Historically, SINTX Technologies' own 3-Year EBITDA Growth Rate has ranged from 64.20 to 91.40 over the past decade. While the company's 10-year median is 88.60 vs. the industry median of 7.65, SINTX Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.65, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SINTX Technologies's current 3-Year EBITDA Growth Rate of 91.40% is 1094.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for SINTX Technologies and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SINTX Technologies's current 3-Year EBITDA Growth Rate is 91.40%, which is near median its own 10-year median of 88.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SINTX Technologies stock overvalued right now?
Based on GuruFocus' analysis, SINTX Technologies (SINT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $1.40 — trading 833.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 91.40%, which is near median its 10-year median of 88.60 and 1094.8% above the Medical Devices & Instruments industry median of 7.65. SINTX Technologies' overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For SINTX Technologies (SINT), the current 3-Year EBITDA Growth Rate is 91.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SINTX Technologies (SINT) Overvalued in 2026?
Based on GuruFocus' analysis, SINTX Technologies stock appears to be overvalued.
The current stock price of $1.40 is trading 833.3% above its estimated GF Value™ of $0.15.
GuruFocus considers SINTX Technologies to be Significantly Overvalued.
Key valuation signals for SINT:
3-Year EBITDA Growth Rate: 91.40% (near median its 10-year median of 88.60)
GF Value™: $0.15 vs. price of $1.40 (833.3% above fair value)
Industry Position: 1094.8% above the Medical Devices & Instruments median (#14 of 692)
No single metric tells the full story. See the SINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.
27GF Score
Get the complete analysis for SINT
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SINT has been successfully added to your 
